Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound.  For many consumers, their insurance denies them ...
Key Takeaways Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of ...
The Other Guys is an action-comedy directed by Adam McKay, starring Will Ferrell and Mark Wahlberg as two mismatched NYPD ...
Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...
With back to back seasons with wins in the double digits, the Missouri Tigers' brand continues to grow at a national level. In 2024, six players ...
The Burton Panthers made quick work of Luling last (Monday) night with a 14-1 victory in a game that was called after just ...
Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches ...
Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.
Can't decide to expand or move to a larger home? Attend the free Build or Renovate event on March 11 to learn more from local ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Investing.com - Eli Lilly (NYSE:LLY) announced on Tuesday that it would begin selling 7.5 milligram and 10 milligram single-dose vials of its Zepbound weight-loss drug at a roughly $150 discount to ...